Dracen Pharmaceuticals, Inc. — Form D
Dracen Pharmaceuticals, Inc. of San Diego, CA, a company, filed a Form D exempt-offering notice with the SEC on 2023-08-10. The offering totals $2.8M, of which $2.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-08-10
- Form: D
- Accession: 0001728955-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.8M
- Amount sold: $2.3M
- Remaining: $500K
- Minimum investment: $3K
- Investors: 6
- Date of first sale: 2023-06-11
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-489348
Issuer
- Name: Dracen Pharmaceuticals, Inc.
- CIK: 0001728955
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 9276 Scranton Road #200, San Diego, CA, 92121
- Phone: 410-659-2777
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Jonathan M Leff | Director | San Diego, CA |
| Drew M Pardoll, M.D., Ph.D. | Director | San Diego, CA |
| Dennis M Bilski | Executive Officer | San Diego, CA |
| Asher M Rubin | Executive Officer | San Diego, CA |
| Thomas M Estok | Director | Carlsbad, CA |
| Thomas M Estok | Executive Officer | Carlsbad, CA |
| Robert M Jackson | Director | Dallas, TX |
Other filings by this issuer (2)
More